MentionFox
Home › Acquisitions › Day One Biopharmaceuticals, Inc.
Completed acquisition · SEC Form 8-K, Item 2.01

Mersana Therapeutics, Inc. acquired by Day One Biopharmaceuticals, Inc.

Before you sign with, sell to or invest in Mersana Therapeutics, Inc.

MentionFox check on Mersana Therapeutics, Inc.: no red flags found in 3 sources; 1 item to note (checked 14 November 2026). mentionfox.com/c/acquisitions/day-one-biopharmaceuticals-mersana-therapeutics-2026-01-06

  • Note: Layoff plan disclosed May 2025 (filing)

New since last check: Layoff plan disclosed May 2025 (filing, first seen 14 November 2026).

Check Mersana Therapeutics, Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Mersana Therapeutics, Inc.?

From Mersana Therapeutics, Inc.'s Form 8-K of 2026-01-06, quoted and linked below.

Mersana Therapeutics, Inc. was acquired by Day One Biopharmaceuticals, Inc. on January 6, 2026, according to the Form 8-K Mersana Therapeutics, Inc. filed with the SEC. The filing states a price of $128.8 million. Each Mersana Therapeutics, Inc. share was converted into the right to receive $30.25 in cash (Form 8-K, January 6, 2026).

2 companies announced an acquisition this week, 1 had other signals.

Companies in an acquisition this week, and the deal. Before you unlock: the company, the deal and what is inside. After: every way we found to reach the company, and anyone a source names. A team joining the buyer is labelled only when the filing itself says so.

InMed Pharmaceuticals Inc.agreed to acquire Mentari
Liberty Capital Corp/NVagreed to acquire Q Gateway Intermediate Holdings, LLC
Check one company free All companies that announced an acquisition this week

Competing with, selling to or investing in Day One Biopharmaceuticals, Inc. after this deal? See the free Snapshot first.

Free to see. No signup.

Day One Biopharmaceuticals, Inc. completed its acquisition of Mersana Therapeutics, Inc. on 2026-01-06, according to the Form 8-K Mersana Therapeutics, Inc. filed with the SEC on 2026-01-06. The filing states a price of $128.8 million. Mersana Therapeutics, Inc. filed the report because the deal made it part of Day One Biopharmaceuticals, Inc..

AcquirerDay One Biopharmaceuticals, Inc.
AcquiredMersana Therapeutics, Inc.
Completed2026-01-06
Price stated in the filing$128.8 million
Reported byMersana Therapeutics, Inc. (MRSN), the company acquired
FilingForm 8-K, filed 2026-01-06

Want the whole picture on Day One Biopharmaceuticals, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Day One Biopharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Day One Biopharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    3 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

What the filing says

Following the consummation of the Offer, pursuant to the terms and conditions of the Merger Agreement, in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the "DGCL") and without a meeting or a vote of the Company's stockholders, on January 6, 2026, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as a direct wholly-owned subsidiary of Parent.

How much did Day One Biopharmaceuticals, Inc. pay for Mersana Therapeutics, Inc.?

The aggregate cash paid by Parent and Merger Sub in the Offer and the Merger on January 6, 2026 was approximately $128.8 million, which was funded by Parent from its available cash on hand.

More from the filing

As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2025, Mersana Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 12, 2025, by and among the Company, Day One Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), and Emerald Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser").
Pursuant to the Merger Agreement, on December 5, 2025, Purchaser commenced a tender offer (the "Offer") to acquire all of the issued and outstanding shares (the "Shares") of common stock, par value $0.0001 per share, of the Company (the "Common Stock"), for (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding(the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR" and collectively, the "CVRs"), which represents the right to receive certain contingent milestone payments of up to an a
The Offer and related withdrawal rights expired as scheduled at one minute after 11:59 p.m., Eastern Time, on January 5, 2026 (such date and time, the "Expiration Time"), and were not extended.

Quoted from Mersana Therapeutics, Inc.'s Form 8-K; also reported in Form 8-K of 2026-01-06.

This is the only completed acquisition Day One Biopharmaceuticals, Inc. reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.

Selling to Day One Biopharmaceuticals, Inc., or weighing an offer there?

Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.

Order Full Report on Day One Biopharmaceuticals, Inc.
Not ready to order?

Look up Day One Biopharmaceuticals, Inc. first. Finding the company and seeing how much is on record uses no credits.

Look up Day One Biopharmaceuticals, Inc.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.

Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.

More on Day One Biopharmaceuticals, Inc.

Cite this page

Permanent URL: https://mentionfox.com/acquisitions/day-one-biopharmaceuticals-mersana-therapeutics-2026-01-06
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3
Mersana Therapeutics, Inc. acquired by Day One Biopharmaceuticals, Inc. for $128.8 million: completed 2026-01-06. MentionFox, 2026-11-14. https://mentionfox.com/acquisitions/day-one-biopharmaceuticals-mersana-therapeutics-2026-01-06